Abstract

Objective: The evaluation of patients with neonatal cholestasis is difficult due to the variety of cholestatic syndromes and non-specific clinical findings. It is important to recognize treatable diseases promptly. The aim of this study is to draw attention to suspicious markers in order to diagnose treatable metabolic diseases.

Method: The presented retrospective study included patients with cholestasis in the first three months of life. The study was conducted between 2018 and 2021 at Diyarbakır Children’s Hospital, Türkiye.

Results: 253 patients presenting with neonatal cholestasis were retrospectively evaluated. 174 patients (68.77%) were examined for intrahepatic cholestasis. 16.6% of the patients were diagnosed with an infection, 13.43% with TPN-related cholestasis, 8.3% with IEM, 7.11% with cystic fibrosis, 4.74% with endocrinopathy, 4.34% patients with Alpha-1 antitrypsin deficiency, 2.76% with idiopathic neonatal hepatitis, 1.97% with genetic syndrome, 1.58% with PFIC, and 0.79% patients with Alagille syndrome. IEM-related patients (21) were diagnosed with tyrosinemia type 1, galactosemia, Niemann-Pick type A, glycogen storage disease type 3, peroxisomal disorders, fatty acid oxidation defects, mitochondrial DNA depletion syndrome, citrine deficiency, Niemann-Pick Type C and bile acid synthesis defect. Plasma tyrosine and methionine levels were high in patients with not only tyrosinemia type 1, but also galactosemia and citrine deficiency. Therapeutic plasma exchange was performed in two patients with fatty acid oxidation disorders.

Conclusion: Neonatal cholestasis poses a diagnostic challenge for clinicians. Delayed referral to a specialist for treatable metabolic diseases may increase mortality and morbidity. IEMs are observed more frequently in the etiologies of neonatal cholestasis in Türkiye due to high parental consanguinity and inadequate newborn screening programs. Treatable disorders should be considered early, as therapeutic interventiosn can be lifesaving. It also helps in genetic counseling, prenatal diagnosis for future pregnancies.

Keywords: Neonatal cholestasis, intrahepatic cholestasis, galactosemia, hereditary tyrosinemia

Copyright and license

Copyright © 2023 The author(s). This is an open-access article published by Aydın Pediatric Society under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Bozacı AE, Demirbaş Ar F, Tekmenuray Ünal A, Taş İ, Bilgin H. The role of inborn errors of metabolism in the etiology of neonatal cholestasis: A single center experience. Trends in Pediatrics. 2023;4(3):161-172. https://doi.org/10.59213/TP.2023.38258

References

  1. Dick MC, Mowat AP. Hepatitis syndrome in infancy-an epidemiological survey with 10 year follow up. Arch Dis Child. 1985;60:512-6. https://doi.org/10.1136/adc.60.6.512
  2. Weiss AK, Vora PV. Conjugated Hyperbilirubinemia in the neonate and young infant. Pediatr Emerg Care. 2018;34:280-3. https://doi.org/10.1097/PEC.0000000000001467
  3. Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2017;64:154-68. https://doi.org/10.1097/MPG.0000000000001334
  4. Hoffmann GF, McKiernan P. Liver Disease. In: Hoffmann GF, Zschocke J, Nyhan W, editors. Inherited Metabolic Diseases. 2nd ed. Heidelberg: Springer; 2017:203-26. https://doi.org/10.1007/978-3-662-49410-3_24
  5. van Spronsen F, Burlina A, Vici CD. Tyrosine Metabolism. In: Nenad Blau N, Vici DC, Ferreira CR, Vianey-Saban C, van Karnebeek CDM, editors. Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases. 2nd ed. Heidelberg: Springer; 2022:353-65. https://doi.org/10.1007/978-3-030-67727-5_21
  6. Christou C, Gika HG, Raikos N, Theodoridis G. GC-MS analysis of organic acids in human urine in clinical settings: a study of derivatization and other analytical parameters. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;964:195-201. https://doi.org/10.1016/j.jchromb.2013.12.038
  7. Gottesman LE, Del Vecchio MT, Aronoff SC. Etiologies of conjugated hyperbilirubinemia in infancy: a systematic review of 1692 subjects. BMC Pediatr. 2015;15:192. https://doi.org/10.1186/s12887-015-0506-5
  8. Moreira-Silva H, Maio I, Bandeira A, Gomes-Martins E, Santos-Silva E. Metabolic liver diseases presenting with neonatal cholestasis: at the crossroad between old and new paradigms. Eur J Pediatr. 2019;178:515-23. https://doi.org/10.1007/s00431-019-03328-5
  9. Sağ E, Öztürk E, Yalçın Cömert H, Aslan Y, Karahan S, Çakır M. Neonatal kolestaz olgularının geriye dönük değerlendirilmesi. J Acad Res Med. 2021;11:90-6. https://doi.org/10.4274/jarem.galenos.2021.25733
  10. Ranucci G, Della Corte C, Alberti D, et al. Diagnostic approach to neonatal and infantile cholestasis: a position paper by the SIGENP liver disease working group. Dig Liver Dis. 2022;54:40-53. https://doi.org/10.1016/j.dld.2021.09.011
  11. Feldman AG, Sokol RJ. Recent developments in diagnostics and treatment of neonatal cholestasis. Semin Pediatr Surg. 2020;29:150945. https://doi.org/10.1016/j.sempedsurg.2020.150945
  12. Morgan MY, Marshall AW, Milsom JP, Sherlock S. Plasma amino-acid patterns in liver disease. Gut. 1982;23:362-70. https://doi.org/10.1136/gut.23.5.362
  13. Lee DY, Kim EH. Therapeutic effects of amino acids in liver diseases: current studies and future perspectives. J Cancer Prev. 2019;24:72-8. https://doi.org/10.15430/JCP.2019.24.2.72
  14. Clayton PT. Inborn errors presenting with liver dysfunction. Semin Neonatol. 2002;7:49-63. https://doi.org/10.1053/siny.2001.0086
  15. Ohura T, Kobayashi K, Tazawa Y, et al. Clinical pictures of 75 patients with neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD). J Inherit Metab Dis. 2007;30:139-44. https://doi.org/10.1007/s10545-007-0506-1
  16. Antonarakis SE, Beckmann JS. Mendelian disorders deserve more attention. Nat Rev Genet. 2006;7:277-82. https://doi.org/10.1038/nrg1826
  17. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 2010;11:31-46. https://doi.org/10.1038/nrg2626